Assessing the cytotoxic and metabolic impact of cebranopadol in a panel of cell lines
DOI:
https://doi.org/10.48797/sl.2026.463Keywords:
PosterAbstract
Background: Cebranopadol is a novel, first-in-class analgesic with a unique pharmacological profile. It acts as a full agonist at the μ-opioid (MOP) and nociceptin/orphanin FQ peptide (NOP) receptors [1]. This dual mechanism shows potential for preserving analgesic potency while reducing adverse effects typical of traditional opioids [2]. Currently, cebranopadol is in phase III clinical trials and has received FDA fast-track designation, reflecting its promise as a next-generation analgesic [3]. Nonetheless, further large-scale studies are necessary to fully establish its safety, long-term efficacy, and comparative advantages over conventional and other emerging opioid analgesics [4]. Objective: The present study aimed to assess the metabolic impact of cebranopadol exposure in three cell lines: BV-2 (murine microglia), HepG2 (human hepatocellular carcinoma) and SH-SY5Y (human neuroblastoma). Methods: Following 48 hours of exposure to half the respective IC50 concentrations, as previously determined through the sulforhodamine B (SRB) assay, BV-2, HepG2, and SH-SY5Y culture medium samples were collected for spectrophotometric quantification of glucose and lactate levels. Results: In BV-2 cells, extracellular glucose levels showed a slight decrease, whereas they remained unchanged in SH-SY5Y and HepG2 cells. Lactate levels increased in culture media samples from cebranopadol-treated BV-2 and SH-SY5Y cells compared to those of the controls, while a decrease was observed in HepG2 cells. These results suggest an opioid-induced shift towards anaerobic metabolism in BV-2 and SH-SY5Y cells, whereas fermentative processes may be hindered in HepG2 cells. Conclusions: While supratherapeutic concentrations of cebranopadol show low cytotoxicity in BV-2, HepG2, and SH-SY5Y cells, they may affect metabolic processes differently across the three cell lines by interfering with aerobic and anaerobic metabolic fluxes. Further investigation of the molecular and cellular mechanisms behind these metabolic alterations is warranted to fully characterize the safety profile of cebranopadol.References
1. Christoph, A. et al. Cebranopadol, a novel first-in-class analgesic drug candidate: first experience in patients with chronic low back pain in a randomized clinical trial. Pain 2017, 158, 1813–24. doi: 10.1097/j.pain.0000000000000986.
2. Wang, A. et al. Novel Opioids in the Setting of Acute Postoperative Pain: A Narrative Review. Pharmaceuticals 2024, 17, doi: 10.3390/ph17010029.
3. Ziemichod, W. et al. Cebranopadol as a Novel Promising Agent for the Treatment of Pain. Molecules 2022, 27, doi: 10.3390/molecules27133987.
4. Coluzzi, F. et al. Current and Future Therapeutic Options in Pain Management: Multi-mechanistic Opioids Involving Both MOR and NOP Receptor Activation. CNS Drugs 2022, 36, 617, doi: 10.1007/s40263-022-00924-2.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Luísa Silva, Beatriz Diogo, Joana Rocha, Margarida Teixeira, Ricardo Jorge Dinis-Oliveira, Juliana Faria, Joana Barbosa
This work is licensed under a Creative Commons Attribution 4.0 International License.
In Scientific Letters, articles are published under a CC-BY license (Creative Commons Attribution 4.0 International License), the most open license available. The users can share (copy and redistribute the material in any medium or format) and adapt (remix, transform, and build upon the material for any purpose, even commercially), as long as they give appropriate credit, provide a link to the license, and indicate if changes were made (read the full text of the license terms and conditions of use).
The author is the owner of the copyright.
